SHANGHAI – Impact Therapeutics Inc., a China-based biotech dedicated to the discovery and development of new drugs, has received $10 million in series B financing from five investors to support the virtual firm's lead candidate, a poly ADP-ribose polymerase (PARP) inhibitor that may have the potential to be best-in-class in China, if not globally. Impact filed for an investigative new drug application (IND) for its PARP-1 inhibitor in China last month.